Clinical Trial Update: Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the impact of adding raltegravir to protease inhibitor monotherapy in HIV-1 infected individuals with sustained viral suppression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Raltegravir (raltegravir)

Snippet

Sponsor: IrsiCaixa | Conditions: HIV-1 Infection | Phase 3 | Status: COMPLETED